Second Evotec BMS Molecular Glue Candidate Reaches IND

Company Evotec; Bristol Myers Squibb Event Type FDA IND acceptance Modality Cereblon E3 ligase modulator (molecular glue) Asset Second partnered candidate (undisclosed) Target Undisclosed Disease Area Undisclosed Summary Evotec reported November 19 that the FDA accepted an IND for a second candidate from its Bristol…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *